Jiangsu Hengrui Medicine Co Ltd - Asset Resilience Ratio
Jiangsu Hengrui Medicine Co Ltd (600276) has an Asset Resilience Ratio of 0.16% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Jiangsu Hengrui Medicine Co Ltd's Asset Resilience Ratio has changed over time. Check 600276 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Jiangsu Hengrui Medicine Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 600276 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥111.45 Million | 0.16% |
| Total Liquid Assets | CN¥111.45 Million | 0.16% |
Asset Resilience Insights
- Limited Liquidity: Jiangsu Hengrui Medicine Co Ltd maintains only 0.16% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Jiangsu Hengrui Medicine Co Ltd Industry Peers by Asset Resilience Ratio
Compare Jiangsu Hengrui Medicine Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Almirall S.A.
MC:ALM |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP |
Drug Manufacturers - Specialty & Generic | 0.63% |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089 |
Drug Manufacturers - Specialty & Generic | 10.89% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
SHG:688505 |
Drug Manufacturers - Specialty & Generic | 11.06% |
Annual Asset Resilience Ratio for Jiangsu Hengrui Medicine Co Ltd (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Jiangsu Hengrui Medicine Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.55% | CN¥273.34 Million ≈ $40.00 Million |
CN¥50.14 Billion ≈ $7.34 Billion |
+0.32pp |
| 2023-12-31 | 0.23% | CN¥99.05 Million ≈ $14.49 Million |
CN¥43.78 Billion ≈ $6.41 Billion |
-6.29pp |
| 2022-12-31 | 6.52% | CN¥2.76 Billion ≈ $403.95 Million |
CN¥42.36 Billion ≈ $6.20 Billion |
-6.45pp |
| 2021-12-31 | 12.96% | CN¥5.09 Billion ≈ $744.88 Million |
CN¥39.27 Billion ≈ $5.75 Billion |
-3.24pp |
| 2020-12-31 | 16.21% | CN¥5.63 Billion ≈ $823.55 Million |
CN¥34.73 Billion ≈ $5.08 Billion |
-14.71pp |
| 2019-12-31 | 30.92% | CN¥8.52 Billion ≈ $1.25 Billion |
CN¥27.56 Billion ≈ $4.03 Billion |
-0.67pp |
| 2018-12-31 | 31.59% | CN¥7.06 Billion ≈ $1.03 Billion |
CN¥22.36 Billion ≈ $3.27 Billion |
+6.36pp |
| 2017-12-31 | 25.22% | CN¥4.55 Billion ≈ $665.84 Million |
CN¥18.04 Billion ≈ $2.64 Billion |
+14.55pp |
| 2016-12-31 | 10.68% | CN¥1.53 Billion ≈ $223.91 Million |
CN¥14.33 Billion ≈ $2.10 Billion |
+7.13pp |
| 2008-12-31 | 3.55% | CN¥80.04 Million ≈ $11.71 Million |
CN¥2.25 Billion ≈ $329.88 Million |
-9.90pp |
| 2007-12-31 | 13.45% | CN¥270.88 Million ≈ $39.64 Million |
CN¥2.01 Billion ≈ $294.67 Million |
+12.70pp |
| 2006-12-31 | 0.75% | CN¥10.97 Million ≈ $1.60 Million |
CN¥1.46 Billion ≈ $213.35 Million |
-4.25pp |
| 2003-12-31 | 5.00% | CN¥72.59 Million ≈ $10.62 Million |
CN¥1.45 Billion ≈ $212.28 Million |
-1.01pp |
| 2002-12-31 | 6.02% | CN¥72.49 Million ≈ $10.61 Million |
CN¥1.20 Billion ≈ $176.27 Million |
-4.93pp |
| 2001-12-31 | 10.95% | CN¥122.49 Million ≈ $17.92 Million |
CN¥1.12 Billion ≈ $163.75 Million |
-1.60pp |
| 2000-12-31 | 12.55% | CN¥123.75 Million ≈ $18.11 Million |
CN¥986.27 Million ≈ $144.32 Million |
-- |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more